Stage IA Patients With Pancreatic Ductal Adenocarcinoma Cannot Benefit From Chemotherapy: A Propensity Score Matching Study

Stage IA Patients With Pancreatic Ductal Adenocarcinoma Cannot Benefit From Chemotherapy: A Propensity Score Matching Study

Purpose: Adjuvant chemotherapy following resection is recommended by clinical practice guidelines for all patients with pancreatic ductal adenocarcinoma (PDAC). This study aimed to evaluate the efficacy of adjuvant chemotherapy among the staging groups of the American Joint Committee on Cancer (AJCC...

Full description

Bibliographic Details
Main Authors: Yuchao Zhang, Gang Xu, Maozhen Chen, Qian Wei, Tengteng Zhou, Ziliang Chen, Mingyang Shen, Ping Wang
Format: Article
Language:English
Published: Frontiers Media S.A. 2020-07-01
Series:Frontiers in Oncology
Subjects:
pancreatic ductal adenocarcinoma
overall survival
chemotherapy
Surveillance
Epidemiology
End Results (SEER)
Online Access:https://www.frontiersin.org/article/10.3389/fonc.2020.01018/full

Internet

https://www.frontiersin.org/article/10.3389/fonc.2020.01018/full

Similar Items